Marleen Kok, MD, PhD, on Triple-Negative Breast Cancer: Results From the TONIC Trial

2017 ESMO Congress
Tweet this page

Marleen Kok, MD, PhD, of The Netherlands Cancer Institute, discusses findings from an adaptive phase II noncomparative trial of nivolumab after induction treatment in triple-negative breast cancer (Abstract LBA14).

Advertisement

Advertisement

Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.